EPRATUZUMAB 90Y

Summary

Epratuzumab 90Y (CHEMBL2108357) is a phase-3 clinical-stage antibody; indicated across 1 condition including b-cell non-hodgkin lymphoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 1 condition
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108357
Name	EPRATUZUMAB 90Y
Type	Antibody
Max phase	3

Also known as: AMG-412, Epratuzumab 90y, HLL2, Lymphocide, EPRATUZUMAB 90Y

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
B-cell non-Hodgkin lymphoma	1	MONDO:0015759	EFO:1001938

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00011908	PHASE1	COMPLETED	Humanized LL2IGG to Treat Systemic Lupus Erythematosus
NCT00054834	PHASE1	TERMINATED	Study of 90Y-hLL2 to Treat Non-Hodgkin’s Lymphoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).